InnoCyte GmbH Finds Further Investors
InnoCyte GmbH has developed a technology that standardizes, automates, accelerates and therefore significantly simplifies and reduces the cost of producing biological cells. The cell production as such is a key process in biological and medical research, for example in the development of medication („pharma screening“) or when creating artificial tissue („tissue engineering“).
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.